Primary aldosteronism: diagnostic and treatment strategies

被引:136
作者
Mattsson, C
Young, WF
机构
[1] Mayo Clin Rochester, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA
[2] Mayo Clin Rochester, Coll Med, Rochester, MN USA
[3] Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden
来源
NATURE CLINICAL PRACTICE NEPHROLOGY | 2006年 / 2卷 / 04期
关键词
adrenalectomy; hyperaldosteronism; mineralocorticoid receptor; potassium; renin;
D O I
10.1038/ncpneph0151
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Primary aldosteronism is caused by bilateral idiopathic hyperplasia in approximately two-thirds of cases and aldosterone-producing adenoma in one-third. Most patients with primary aldosteronism are normokalemic. In the clinical setting of normokalemic hypertension, patients who have resistant hypertension and hypertensive patients with a family history atypical for polygenic hypertension should be tested for primary aldosteronism. The ratio of plasma aldosterone concentration to plasma renin activity has been generally accepted as a first-line case-finding test. If a patient has an increased ratio, autonomous aldosterone production must be confirmed with an aldosterone suppression test. Once primary aldosteronism is confirmed, the subtype needs to be determined to guide treatment. The initial test in subtype evaluation is CT imaging of the adrenal glands. If surgical treatment is considered, adrenal vein sampling is the most accurate method for distinguishing between unilateral and bilateral adrenal aldosterone production. Optimal treatment for aldosterone-producing adenoma or unilateral hyperplasia is unilateral laparoscopic adrenalectomy. The idiopathic bilateral hyperplasia and glucocorticoid-remediable aldosteronism subtypes should be treated pharmacologically. All patients treated pharmacologically should receive a mineralocorticoid receptor antagonist, a drug type that has been shown to block the toxic effects of aldosterone on nonepithelial tissues.
引用
收藏
页码:198 / 208
页数:11
相关论文
共 91 条
[1]   Captopril suppression versus salt loading in confirming primary aldosteronism [J].
Agharazii, M ;
Douville, P ;
Grose, JH ;
Lebel, M .
HYPERTENSION, 2001, 37 (06) :1440-1443
[2]  
ANDERSEN GS, 1988, J HUM HYPERTENS, V2, P187
[3]   Laparoscopic adrenalectomy [J].
Assalia, A ;
Gagner, M .
BRITISH JOURNAL OF SURGERY, 2004, 91 (10) :1259-1274
[4]   PREVALENCE OF PRIMARY AND SECONDARY HYPERTENSION - STUDIES IN A RANDOM POPULATION-SAMPLE [J].
BERGLUND, G ;
ANDERSSON, O ;
WILHELMSEN, L .
BRITISH MEDICAL JOURNAL, 1976, 2 (6035) :554-556
[5]   DIAGNOSIS AND TREATMENT OF PRIMARY HYPERALDOSTERONISM [J].
BLUMENFELD, JD ;
SEALEY, JE ;
SCHLUSSEL, Y ;
VAUGHAN, ED ;
SOS, TA ;
ATLAS, SA ;
MULLER, FB ;
ACEVEDO, R ;
ULICK, S ;
LARAGH, JH .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (11) :877-885
[6]   REMODELING OF THE RAT RIGHT-AND-LEFT-VENTRICLES IN EXPERIMENTAL-HYPERTENSION [J].
BRILLA, CG ;
PICK, R ;
TAN, LB ;
JANICKI, JS ;
WEBER, KT .
CIRCULATION RESEARCH, 1990, 67 (06) :1355-1364
[7]   Aldosterone and end-organ damage [J].
Brown, NJ .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2005, 14 (03) :235-241
[8]   Hyperaldosteronism among with resistant black and white subjects hypertension [J].
Calhoun, DA ;
Nishizaka, MK ;
Zaman, MA ;
Thakkar, RB ;
Weissmann, P .
HYPERTENSION, 2002, 40 (06) :892-896
[9]   MYOCARDIAL FIBROSIS IN THE RAT WITH MINERALOCORTICOID EXCESS - PREVENTION OF SCARRING BY AMILORIDE [J].
CAMPBELL, SE ;
JANICKI, JS ;
MATSUBARA, BB ;
WEBER, KT .
AMERICAN JOURNAL OF HYPERTENSION, 1993, 6 (06) :487-495
[10]  
Celen O, 1996, ARCH SURG-CHICAGO, V131, P646